CorMedix (CRMD) PT Raised to $18 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $7.70 -6.1%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 23 | New: 16
Join SI Premium – FREE
Truist Securities analyst Joon Lee raised the price target on CorMedix (NASDAQ: CRMD) to $18.00 (from $16.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Teladoc (TDOC) PT Raised to $6.50 at Stifel
- Bicycle Therapeutics (BCYC) PT Lowered to $10 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
